190 related articles for article (PubMed ID: 12374901)
1. PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: the PERFECT study--sub study of EUROPA: rationale and design.
Bots ML; Remme WJ; Lüscher TF; Grobbee DE;
Cardiovasc Drugs Ther; 2002 May; 16(3):227-36. PubMed ID: 12374901
[TBL] [Abstract][Full Text] [Related]
2. ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.
Bots ML; Remme WJ; Lüscher TF; Fox KM; Bertrand M; Ferrari R; Simoons ML; Grobbee DE;
Cardiovasc Drugs Ther; 2007 Aug; 21(4):269-79. PubMed ID: 17657599
[TBL] [Abstract][Full Text] [Related]
3. EUROPA substudies, confirmation of pathophysiological concepts. European trial on reduction of cardiac events with perindopril in stable coronary artery disease.
Simoons ML; Vos J; de Feyter PJ; Bots ML; Remme WJ; Grobbee DE; Kluft C; de Maat MP; Fox KM; Deckers JW
Eur Heart J; 1998 Sep; 19 Suppl J():J56-60. PubMed ID: 9796842
[TBL] [Abstract][Full Text] [Related]
4. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
5. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
Ferrari R; Fox K
Drugs; 2009; 69(3):265-77. PubMed ID: 19275271
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Fox KM;
Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
[TBL] [Abstract][Full Text] [Related]
7. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
[TBL] [Abstract][Full Text] [Related]
8. The EUROPA trial: design, baseline demography and status of the substudies.
Gomma AH; Fox KM
Cardiovasc Drugs Ther; 2001 Mar; 15(2):169-79. PubMed ID: 11669411
[TBL] [Abstract][Full Text] [Related]
9. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?
Remme WJ
Drugs; 1997; 54 Suppl 5():59-70. PubMed ID: 9429846
[TBL] [Abstract][Full Text] [Related]
10. The sympathetic nervous system and ischaemic heart disease.
Remme WJ
Eur Heart J; 1998 Jun; 19 Suppl F():F62-71. PubMed ID: 9651738
[TBL] [Abstract][Full Text] [Related]
11. PERTINENT--perindopril-thrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a sub-study of the EUROPA study.
Scientific Committee of the PERTINENT Sub-Study, EUROPA-PERTINENT Investigators
Cardiovasc Drugs Ther; 2003 Jan; 17(1):83-91. PubMed ID: 12843690
[TBL] [Abstract][Full Text] [Related]
12. Large and small artery endothelial function in patients with essential hypertension--effect of ACE inhibition and beta-blockade.
Buus NH; Jørgensen CG; Mulvany MJ; Sørensen KE
Blood Press; 2007; 16(2):106-13. PubMed ID: 17612909
[TBL] [Abstract][Full Text] [Related]
13. Evidence for benefits of perindopril in hypertension and its complications.
Laurent S
Am J Hypertens; 2005 Sep; 18(9 Pt 2):155S-162S. PubMed ID: 16125052
[TBL] [Abstract][Full Text] [Related]
14. Divergent effects of angiotensin-converting enzyme inhibition on blood pressure and endothelial function in obese humans.
Williams IL; Chowienczyk PJ; Wheatcroft SB; Patel AG; Sherwood RA; Shah AM; Kearney MT
Diab Vasc Dis Res; 2006 May; 3(1):34-8. PubMed ID: 16784179
[TBL] [Abstract][Full Text] [Related]
15. Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.
Bertrand ME; Remme WJ; Fox KM; Ferrari R; Simoons ML;
Int J Cardiol; 2007 Sep; 121(1):57-61. PubMed ID: 17270296
[TBL] [Abstract][Full Text] [Related]
16. [Effect of 6-month therapy with perindopril A on structural-functional state of arterial vascular bed in patients with chronic heart failure].
Belenkov IuN; Privalova EV; Danilogorskaia IuA; Zheleznykh EF; Shchendrygina AA
Kardiologiia; 2014; 54(2):4-7. PubMed ID: 24888193
[TBL] [Abstract][Full Text] [Related]
17. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
Fox KM; Henderson JR; Bertrand ME; Ferrari R; Remme WJ; Simoons ML
Eur Heart J; 1998 Sep; 19 Suppl J():J52-5. PubMed ID: 9796841
[TBL] [Abstract][Full Text] [Related]
18. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease.
Zhuo JL; Mendelsohn FA; Ohishi M
Hypertension; 2002 Feb; 39(2 Pt 2):634-8. PubMed ID: 11882622
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study).
Anderson TJ; Elstein E; Haber H; Charbonneau F
J Am Coll Cardiol; 2000 Jan; 35(1):60-6. PubMed ID: 10636260
[TBL] [Abstract][Full Text] [Related]
20. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure.
Hornig B; Arakawa N; Drexler H
Eur Heart J; 1998 Jul; 19 Suppl G():G48-53. PubMed ID: 9717056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
